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CDK16 (also known as PCTAIRE1 or PCTK1) is an atypical member of the cyclin-dependent
kinase (CDK) family that has emerged as a key regulator of neurite outgrowth, vesicle trafﬁck-
ing and cancer cell proliferation. CDK16 is activated through binding to cyclin Y via a phos-
phorylation-dependent 14-3-3 interaction and has a unique consensus substrate
phosphorylation motif compared with conventional CDKs. To elucidate the structure and
inhibitor-binding properties of this atypical CDK, we screened the CDK16 kinase domain
against different inhibitor libraries and determined the co-structures of identiﬁed hits. We dis-
covered that the ATP-binding pocket of CDK16 can accommodate both type I and type II
kinase inhibitors. The most potent CDK16 inhibitors revealed by cell-free and cell-based
assays were the multitargeted cancer drugs dabrafenib and rebastinib. An inactive DFG-out
binding conformation was conﬁrmed by the ﬁrst crystal structures of CDK16 in separate
complexes with the inhibitors indirubin E804 and rebastinib, respectively. The structures
revealed considerable conformational plasticity, suggesting that the isolated CDK16 kinase
domain was relatively unstable in the absence of a cyclin partner. The unusual structural fea-
tures and chemical scaffolds identiﬁed here hold promise for the development of more
selective CDK16 inhibitors and provide opportunity to better characterise the role of CDK16
and its related CDK family members in various physiological and pathological contexts.
Introduction
CDK16 is a newly recognised member of the CDK protein kinase family [1,2] that is activated upon
binding to the membrane-associated protein cyclin Y (CCNY) or its homologue cyclin Y-like 1
(CCNYL1) [3–5]. These interactions are facilitated by a ‘PCTAIRE’ sequence motif in the kinase αC
helix that is conserved in CDK17 and CDK18, but diverged from the classical ‘PSTAIRE’ motif found
in CDK2 [6]. CDK16 and cyclin Y contain central kinase and cyclin box domains, respectively, both
ﬂanked by N- and C-terminal extensions that form sites of regulatory phosphorylation [5,7].
Phosphorylations at Ser100 and Ser326 in cyclin Y promote an additional interaction with 14-3-3
protein that also appears necessary for its binding to and activation of CDK16 [5,8].
CDK16 is ubiquitously expressed, but is particularly high in terminally differentiated cells and in the
brain, where it is suggested to control neurite outgrowth [7,9]. In addition, CDK16 is highly expressed in
the testis where it plays a unique role in the terminal steps of spermatogenesis [3,4]. Genetic knockdown
in Caenorhabditis elegans has suggested parallel roles for a CDK16-18 orthologue (PCT-1) and CDK5 in
the inhibition of retrograde axonal trafﬁcking [10]. CDK16 has also been implicated in other diverse pro-
cesses, including vesicle trafﬁcking [11,12], glucose homeostasis [13,14] and muscle differentiation [15].
In addition to these important biological functions, CDK16 has been implicated in the growth of
several cancers [16] and its expression has been found to be signiﬁcantly elevated in tissues derived
from prostate and breast cancers [17]. In agreement, siRNA-mediated knockdown of CDK16 has been
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shown to inhibit the proliferation of medulloblastoma, prostate, breast, melanoma and cervical cancer cell lines
[16,18,19]. Furthermore, CDK16 knockdown reduced tumour volume in mouse xenograft models of colorectal
cancer [20]. Interestingly, CDK16 knockdown did not affect proliferation in non-transformed cells [16]. Taken
together, these data identify CDK16 as a potential target for the development of novel anti-cancer drugs.
However, the mechanism by which CDK16 is involved in cancer cell growth is unknown and selective small-
molecule inhibitors for CDK16 have not been identiﬁed.
Here, we show that the kinase domain of CDK16 can bind to a diverse set of chemical inhibitor scaffolds,
but has a broad preference for known CDK inhibitors, consistent with its sequence homology. Of note for
future chemistry efforts, both type I and type II kinase inhibitors are among the most potent CDK16 inhibitors,
as exempliﬁed by the clinically tested compounds dabrafenib and rebastinib, respectively. We further conﬁrm
that these compounds can bind to full-length (FL) CDK16 in intact cells. In addition, we report the ﬁrst crystal
structures of CDK16 in separate complexes with the inhibitors indirubin E804 and rebastinib, respectively. The
structures reveal considerable conformational plasticity. In particular, the partial unfolding of the αC helix in
the indirubin E804 co-structure suggests that the isolated CDK16 kinase domain may be relatively unstable in
the absence of a cyclin partner. Potentially, this unusual αC structure could be exploited in future to develop
more selective CDK16 inhibitors.
Materials and methods
Materials
PCTAIRE-tide (PKSPKARKKL) peptide substrate for CDK16 kinase assays was synthesised by GL Biochem.
[γ-32P]ATP was obtained from PerkinElmer. Cell culture reagents were obtained from Life Technologies.
Preclinical kinase inhibitors were obtained from Calbiochem. Clinical kinase inhibitors were obtained from the
FIMM drug collection. Published kinase inhibitor set (PKIS) compounds were a gift from William Zuercher
Figure 1. Chemical scaffolds of identiﬁed CDK16 inhibitors.
Compounds shown induced a Tm shift for CDK16 of >7°C.
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(GlaxoSmithKline). P81 paper was obtained from Whatman. Unless otherwise indicated, all other reagents
were obtained from Sigma.
Antibodies
Anti-CDK16 antibody (HPA001366) was obtained from Sigma. Anti-glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) (G9) antibody (sc-365062) was obtained from Santa Cruz Biotechnology. Anti-haemagglutinin
(HA) antibody (HA.11) was from Covance Research Products and anti-FLAG antibody (F7425) was from
Sigma. Site-speciﬁc rabbit polyclonal antibodies against phospho-cyclin Y (pSer12, pSer100, pSer326 and
pSer336) were described recently [5]. Horseradish peroxidase-conjugated secondary antibodies used in Figures
3 and 4 were from Jackson ImmunoResearch. Anti-rabbit IgG (Sigma, #A6667) and anti-mouse IgG (Dako)
were used in experiments shown in Figure 5.
Plasmids
All plasmid constructs were generated using standard molecular biology techniques. Cloning and mutagenesis
of the coding regions of CDK16 isoform 1 (NM_006201.4) and cyclin Y (NM_145012.4) used in Figures 2–4
have been described recently [5]. Brieﬂy, FL CDK16 was cloned into the mammalian expression vector
pCMVFLAG-2, whereas FL cyclin Y was cloned into pCMVHA-1. The kinase-inactive D304A mutant of
CDK16 and phospho-deﬁcient S336A mutant of cyclin Y were prepared using the QuikChange method
(Agilent) and KOD Hot Start DNA Polymerase (Novagen). For structural and inhibitor screening work, human
CDK16163–478 with the phosphomimetic S319D mutation was cloned into the bacterial expression vector
pNIC-CH, which encodes for a non-cleavable C-terminal hexahistidine tag.
Protein expression and puriﬁcation
Protein expression used the Escherichia coli strain BL21 (DE3) additionally transformed with the plasmid
pRARE2. Cultures were grown at 37°C to the mid-log phase in Luria–Bertani broth media and protein expres-
sion was induced overnight at 18°C with 0.5 mM isopropyl β-D-1-thiogalactopyranoside. Cells were harvested
by centrifugation and lysed by ultrasonication in a buffer containing 50 mM HEPES (pH 7.5), 500 mM NaCl,
5% glycerol, 5 mM imidazole, 1 mM phenylmethylsulphonyl ﬂuoride (PMSF), 0.5 mM tris(2-carboxyethyl)
phosphine (TCEP). The cell lysate was then clariﬁed by centrifugation. CDK16 protein was puriﬁed initially
using nickel sepharose chromatography (GE Healthcare) and eluted stepwise with imidazole. Further puriﬁca-
tion was performed by size-exclusion chromatography using a HiLoad Superdex S200 16/60 column
(GE Healthcare) buffered in 50 mM HEPES (pH 7.5), 300 mM NaCl and 0.5 mM TCEP. For crystallisation
with indirubin E804, a ﬁnal clean-up step was also performed by anion exchange chromatography using a
Figure 2. In vitro inhibition of CDK16 activity.
E. coli-puriﬁed CDK16 (125 ng) was incubated with rebastinib (A), dabrafenib (B) or indirubin E804 (C) for 5 min followed by the addition of
COS1-puriﬁed FLAG-cyclin Y (125 ng) and assayed for kinase activity using PCTAIRE-tide as described in ‘Materials and Methods’. Curves were
ﬁtted using non-linear regression to the log (inhibitor) vs. response (variable slope) equation using the Graphpad Prism software. Results are
expressed as mean ± SD and are shown as percentage activity relative to non-treated kinase, and represent the average of three independent
experiments performed using the same protein preparations.
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monoQ column buffered in 50 mM Tris (pH 9.0) with a gradient of 0–1.0 M NaCl. The correct intact mass of
the protein was conﬁrmed by mass spectrometry.
Differential scanning ﬂuorimetry
Thermal melting experiments were performed using a Real-Time PCR machine Mx3005p (Stratagene) as
described previously [21]. Brieﬂy, 2 μM CDK16 was screened against a collection of kinase inhibitors in a
96-well plate format. Compounds were added to a ﬁnal concentration of 12.5 μM in an assay buffer containing
10 mM HEPES (pH 7.4), 150 mM NaCl and SYPRO Orange (1:1000 dilution, Sigma). Fluorescence was moni-
tored as samples were heated from 25 to 96°C. Data were analysed with the MxPro software. Thermal shift
values induced by inhibitor binding were calculated relative to control wells containing protein and 2.5%
dimethyl sulfoxide (DMSO).
Figure 3. Cellular inhibition of CDK16.
HA-cyclin Y WT or S336A mutant was co-transfected with FLAG-CDK16 WT or D304A kinase-inactive mutant in COS1 cells as
indicated. Cells were treated for 1 h with varying concentrations of the indicated inhibitors, and cell lysates were
immunoblotted using the indicated antibodies. FLAG immunoblot is representative of all three inhibitors. For other immunoblots
(HA, pSer12, pSer100, pSer326 and pSer336), three separate blots (Reb, Dab and Indi) were exposed in the same X-ray ﬁlm
following incubation with enhanced chemiluminescence reagent. Reb, rebastinib; Dab, dabrafenib; Indi, indirubin E804.
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In vitro CDK16 kinase assay
In vitro CDK16 kinase assay was performed as described recently [5]. E. coli-puriﬁed human CDK16 (125 ng)
was incubated with varying concentrations of compound for 5 min followed by the addition of COS1-puriﬁed
FLAG-human cyclin Y (125 ng) bound to endogenous 14-3-3 and assayed for phosphotransferase activity at
30°C for 30 min in a ﬁnal assay volume of 50 ml containing 50 mM HEPES (pH 7.5), 0.1 mM EGTA, 10 mM
magnesium acetate, 0.1 mM [γ-32P]ATP (300 c.p.m./pmol), 0.03% Brij 35, 1 mM dithiothreitol (DTT) and
50 mM of the CDK16 substrate PCTAIRE-tide (PKSPKARKKL) [22]. Reactions were terminated by spotting
onto P81 paper and immersion in 75 mM H3PO4. After washing with H3PO4, P81 papers were air-dried and
incorporation of γ-32P was determined by Cherenkov counting. IC50 values were determined using three inde-
pendent experiments.
Cellular CDK16 kinase assay and cyclin Y binding
COS1 cells were maintained in high-glucose Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
(v/v) foetal bovine serum (FBS) under 5% CO2. Cells were transfected with DNA constructs [wild-type (WT)
or mutant of human FLAG-CDK16 and HA-cyclin Y] using polyethyleneimine and 24 h later treated with
varying concentrations of compound for 1 h. Cells were then washed with ice-cold phosphate-buffered saline
(PBS) and scraped into lysis buffer [50 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 270 mM sucrose,
1% (w/v) Triton X-100, 50 mM NaF, 5 mM Na4P2O7, 1 mM Na3VO4, 1 mM DTT, 1 mM benzamidine and
0.5 mM PMSF]. Lysates were centrifuged at 17 000 g for 10 min at 4°C and stored at −80°C. Protein concentra-
tion was determined using Bradford reagent and BSA standard. Lysates were immunoblotted with the CDK16
kinase activity-dependent (Ser336) or -independent (Ser12, Ser100 and Ser326) site-speciﬁc phospho-cyclin Y
antibodies as the surrogate marker for speciﬁc and non-speciﬁc cellular CDK16 activity [5]. The compound-
treated lysates were also immunoprecipitated using FLAG-agarose and immunoblotted using HA (cyclin Y)
and 14-3-3 antibodies to assess the effect of the compounds on CDK16–cyclin Y binding.
Cellular thermal shift assay
Cellular thermal shift assay (CETSA) experiments were performed as described previously [23,24]. IGR-37
melanoma cells were seeded into a T75cm2 ﬂask at a density of 5 × 106 cells/ml. After 24 h, the cells were
treated for 30 min with cell media [RPMI supplemented with 10% (v/v) FBS and 1% penicillin/streptomycin]
containing either 20 mM rebastinib or vehicle (0.08% DMSO). After treatment, cells were collected by centrifu-
gation and washed in 1× PBS (5.5 ml). The cells were resuspended in 1 ml of PBS and the cell suspension was
aliquoted at 90 μl into PCR tubes. Following further centrifugation, all 1× PBS was removed before the cells
were heated for 3 min at 37, 41, 45, 49, 53, 57, 61, 65, 69 or 73°C. Subsequently, cells were lysed in 120 ml of
lysis buffer [50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 0.8% NP-40, 5% glycerol, 1.5 mM MgCl2, 25 mM NaF,
1 mM Na3VO4, 1 mM PMSF, 1 mM DTT, 10 mg/ml TLCK, 1 mg/ml leupeptin, 1 mg/ml aprotinin and
10 mg/ml soybean trypsin inhibitor (Sigma, pH 7.5)] by three consecutive freeze–thaw cycles using liquid nitrogen.
The soluble fraction was separated from precipitated materials by centrifugation at 16 200 g and 4°C for
Figure 4. Rebastinib and dabrafenib inhibit CDK16–cyclin Y binding.
HA-cyclin Y WT was co-transfected with FLAG-CDK16 WT or D304A kinase-inactive mutant in COS1 cells as indicated and
cells were treated for 1 h with 10 μM of the indicated inhibitors (same lysates as in Figure 3). Cell lysates were
immunoprecipitated with FLAG-agarose and immunoblotted using the indicated antibodies. Reb, rebastinib; Dab, dabrafenib;
Indi, indirubin E804.
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20 min. The supernatant, containing the soluble proteins, was transferred to a fresh tube and analysed by
immunoblotting (IB).
Crystallisation
For the indirubin E804 complex, CDK16 protein was buffered in 25 mM HEPES (pH 7.5), 250 mM NaCl, 5%
glycerol and 10 mM DTT. Protein was concentrated to 15 mg/ml in the presence of the inhibitor (ﬁnal inhibi-
tor concentration of 1 mM). Crystals were grown by micro-seeding at 20°C in 130 nl of sitting drops, mixing
96 nl of protein solution with 10 nl of micro-seed solution (crystals prepared from the same precipitant) and
24 nl of a reservoir solution containing 2.1 M Na-formate (pH 7.0), 0.1 M Bis–Tris (pH 7.0). On mounting,
crystals were cryoprotected with reservoir solution mixed with 25% glycerol and vitriﬁed in liquid nitrogen.
For the rebastinib complex, CDK16 protein was buffered in 25 mM HEPES (pH 7.5), 150 mM NaCl, 5% gly-
cerol and 10 mM DTT. CDK16 at 5 mg/ml was mixed with an 1.5 mM inhibitor and concentrated further to
16.4 mg/ml. Crystals were grown at 20°C in 200 nl of sitting drops, mixing 150 nl of protein solution with
50 nl of a reservoir solution containing a 25% PEG smear (PEG2000, PEG3350, PEG4000 and PEG5000MME)
and 0.1 M citrate (pH 5.5). Before mounting, crystals were cryoprotected with mother liquor supplemented
with an additional 25% ethylene glycol and vitriﬁed in liquid nitrogen.
Structure determination
Diffraction data for the CDK16 complex with indirubin E804 were collected on one crystal at 100 K on beam-
line I03 of the Diamond Light Source. Data were integrated with XDS [25] and scaled with SCALA [26]. The
structure was solved by molecular replacement with PHASER [27] using the structure of CDK5 (PDB ID:
1UNL) as a search model. Reﬁnement was performed with BUSTER [28] combined with manual rebuilding in
COOT [29]. The quality of the model was validated with MOLPROBITY [30].
Diffraction data for the CDK16 complex with rebastinib were collected on one crystal at 100 K on Diamond
Light Source beamline I02. Data were indexed and integrated using MOSFLM [31] and then scaled with
AIMLESS [32]. Initial phases were calculated in PHASER using the ﬁrst CDK16 structure as a model for
molecular replacement [27]. After obtaining the initial electron density maps by rigid body reﬁnement in
REFMAC5 [33], a structural model was generated by automated building in Buccaneer [34]. Several rounds of
non-crystallographic symmetry restrained reﬁnement were then performed in REFMAC5 [33] combined with
manual modelling with COOT [29]. The reﬁned structures were validated with MolProbity [30]. Structure
ﬁgures were prepared with PyMOL [35].
Figure 5. Rebastinib binding to endogenous CDK16 is conﬁrmed by CETSA.
Aliquots of IGR-37 melanoma cells were treated with either rebastinib (20 mM) or vehicle (DMSO) and then heated for 3 min at
indicated temperatures. CDK16 and GAPDH protein levels were then assessed by IB. Immunoreactive bands speciﬁc for
CDK16 were conﬁrmed using CDK16 knockdown cells; the middle band of the three observed was found to be non-speciﬁc
(Supplementary Figure S1).
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Results
CDK16 binds type I and type II kinase inhibitors
To identify protein constructs suitable for structural studies, human CDK16 was recombinantly expressed in
E. coli with a variety of N- and C-terminal truncations. A viable construct CDK16163–478 was identiﬁed that
was amenable to crystallisation when expressed with a C-terminal hexahistidine tag and the activation segment
mutation S319D. To identify potential inhibitors of CDK16, we screened the recombinant protein kinase
domain against many inhibitor libraries using differential scanning ﬂuorimetry (DSF). Ligands in this assay
increase a protein’s melting temperature (Tm shift, ΔTm) by an amount proportional to their binding afﬁnity. A
Tm shift of 8°C or higher is typically observed for compounds binding with a KD value of 100 nM or less [36].
Screening against signalling inhibitors obtained from Calbiochem revealed that the most potent hits were
known type I inhibitors of the CDK family, conﬁrming the similarity of CDK16 to classical CDKs such as
CDK2 (Table 1 and Supplementary Table S1). These included the triazolo-diamine compound Cdk1/2
Inhibitor III (ΔTm = 9.6°C), Alsterpaullone, 2-Cyanoethyl (ΔTm = 7.9°C), Indirubin E804 (ΔTm = 7.6°C) and the
aminopyrimidinyl compound Cdk2/9 Inhibitor (ΔTm = 7.2°C; Figure 1). A similar preference was observed
upon screening of the PKIS (Table 1 and Supplementary Table S2) [37]. Again, the most potent hits with
Tm shift values above 8°C were known CDK2 inhibitors, including the oxindoles GW300657X and
GW416981X, as well as the pyrazolo[1,5-b]pyridazine compound GW779439X (Figure 1) [37].
We also screened ∼150 kinase inhibitors (FIMM drug collection) that have either entered clinical trials or
been approved by the US Food and Drug Administration. While many moderate binders were observed, two
compounds produced exceptional Tm shift values far exceeding those from the previous screening (Table 1 and
Supplementary Table S3). The most potent hit was rebastinib (DCC-2036), which yielded a Tm shift of 12.6°C.
Rebastinib is a multitargeted type II kinase inhibitor that was developed to inhibit BCR-ABL as well as the
drug-resistant gatekeeper mutant ABLT315I (Figure 1) [25]. It has entered phase I clinical trials for chronic
myeloid leukaemia [25]. The other signiﬁcant hit was dabrafenib (GSK2118436), which showed a Tm shift of
10.4°C. Dabrafenib is an ATP-competitive type I inhibitor of mutant BRAFV600E that has been approved for
clinical use in advanced melanoma [26]. Other clinically relevant inhibitors yielding a Tm shift of 5°C or more
included many CDK inhibitors, such as SNS-032 (7.0°C), milciclib (6.2°C) and dinaciclib (5.5°C). Thus,
CDK16 has a propensity to bind both type I and type II inhibitors and has a broad preference for inhibitors
targeted to other CDK kinases (Figure 1).
Rebastinib and dabrafenib are potent inhibitors of CDK16
Shehata et al. [5] demonstrated previously that recombinant FL CDK16 from bacterial expression can be acti-
vated by COS1-puriﬁed recombinant cyclin Y, which co-puriﬁes with endogenous 14-3-3. We therefore used
this activation strategy to perform an in vitro kinase assay to determine the IC50 values of selected inhibitors.
Varying concentrations of each compound were preincubated with E. coli-puriﬁed CDK16 for 5 min, followed
by the addition of COS1-puriﬁed cyclin Y/14-3-3 complex. CDK16 was then assayed for phosphotransferase
Table 1 Top hits from DSF screening
Calbiochem collection Tm shift (°C) PKIS collection Tm shift (°C) Clinical inhibitors Tm shift (°C)
Cdk1/2 Inhibitor III 9.6 GW300657X 8.8 Rebastinib 12.6
Alsterpaullone, 2-Cyanoethyl 7.9 GW416981X 8.7 Dabrafenib 10.4
Indirubin E804 7.6 GW779439X 8.1 SNS-032 7.0
Cdk2/9 Inhibitor 7.2 GW300660X 6.8 Milciclib 6.2
Aurora/Cdk Inhibitor 6.7 GW301784X 6.0 AZ23 5.8
(Z,E)-3-(imidazol-4-ylmethylene)indolin-2-one 6.7 GSK238583A 5.8 AT9283 5.7
Indirubin-30-monoxime-5-sulphonic acid 6.7 SB-732881-H 5.5 Ponatinib 5.5
Flt3 Inhib III 6.6 SB-739245-AC 5.4 Dinaciclib 4.8
5-Iodo-indirubin-30-monoxime 6.1 SB-732881 5.2 PIK-75 4.7
SU9516 6.0 GW780056X 4.8 Regorafenib 4.1
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activity against the optimised substrate PCTAIRE-tide (PKSPKARKKL) (Figure 2) [22]. Rebastinib and dabrafe-
nib showed comparable IC50 values of 32 and 35 nM, respectively, whereas indirubin E804 exhibited weaker
inhibition with an IC50 value of 83 nM. Overall, these data are in good agreement with the DSF assay results,
which yielded the same rank order of potencies (Table 1).
Rebastinib inhibits CDK16 activity in cells
We next tested the ability of the compounds to inhibit CDK16 activity in intact cells. It was shown recently
that Ser336 phosphorylation on cyclin Y is dependent on CDK16 kinase activity [5]. We therefore tested
whether inhibitor treatment would affect Ser336 phosphorylation using a phospho-speciﬁc antibody.
HA-tagged cyclin Y WT or S336A mutant was co-expressed with FLAG-tagged CDK16 WT or D304A
(kinase-inactive) mutant in COS1 cells. The cells were treated with increasing concentrations of the respective
inhibitors (rebastinib, dabrafenib or indirubin E804) for 1 h, and lysates were immunoblotted for detection of
Ser336–cyclin Y phosphorylation. As shown in Figure 3, Ser336 phosphorylation decreased in a dose-
dependent manner with all of the inhibitors tested. While rebastinib and dabrafenib showed comparable IC50
values in cell-free assays, rebastinib treatment resulted in a signiﬁcantly more potent inhibitory effect in COS1
cells compared with dabrafenib and indirubin E804. No detectable Ser336 phosphorylation was observed in the
kinase-inactive (D304A) CDK16 or phospho-deﬁcient (S336A) cyclin Y mutant controls, conﬁrming the
requirement for CDK16 activity and speciﬁcity of the phospho-Ser336–cyclin Y antibody as recently reported
[5]. To further demonstrate the speciﬁcity of the inhibitors, we tested the phosphorylation status of three other
sites within the cyclin Y protein that are known to be independent of CDK16 activity [5]. Importantly, there
was no signiﬁcant change in the phosphorylation of Ser12, Ser100 or Ser326, conﬁrming that the inhibitors
were acting speciﬁcally through CDK16 (Figure 3).
The three tested inhibitors are expected to have three different binding modes that may differentially affect
the binding of CDK16 to the cyclin Y/14-3-3 complex. While indirubin E804 is compatible with an active
kinase conformation [38], rebastinib and dabrafenib are expected to bind to inactive ‘DFG-out, αC-in’ and
‘DFG-in, αC-out’ kinase conformations, respectively, that may hinder cyclin Y association [39,40]. To test this
hypothesis, we immunoprecipitated FLAG-tagged CDK16 from variously treated COS-1 cells and performed IB
for HA-tagged cyclin Y and endogenous 14-3-3 protein. Both CDK16 WT and the D304A kinase-inactive
mutant were able to immunoprecipitate cyclin Y and 14-3-3 protein, conﬁrming that their association with
CDK16 was independent of CDK16 kinase activity (Figure 4). However, the amounts of cyclin Y and 14-3-3 in
these immunoprecipitates were dramatically reduced upon prior treatment of the cells with either rebastinib or
dabrafenib (Figure 4). The low amounts of 14-3-3 protein still detected in these immunoprecipitates potentially
indicate some direct association of the 14-3-3 with CDK16 [7]. In contrast, treatment with indirubin E804 had
no effect (Figure 4). These data strongly suggest that rebastinib and dabrafenib induce structural changes in the
monomeric CDK16 that sterically interferes with its binding to cyclin Y.
The binding of rebastinib to endogenous CDK16 was additionally conﬁrmed by a CETSA, a recently devel-
oped methodology which takes advantage of alterations in protein thermal stability upon ligand binding
[23,24]. Aliquots of IGR-37 melanoma cells were treated with either rebastinib (20 mM) or vehicle (DMSO)
and then heated for 3 min at different temperatures ranging from 37 to 73°C. CDK16 protein levels were then
assessed by IB. In the DMSO-treated control cells, CDK16 was stable up to 49°C, whereas rebastinib protected
CDK16 from unfolding at higher temperatures up to 57°C (Figure 5). We veriﬁed that the immunoreactive
bands (CDK16) were speciﬁc using CDK16 knockdown cells as controls (Supplementary Figure S1). These
results are consistent with the large thermal shift observed in the initial compound library screen (Table 1).
Structure determination
Crystallisation trials using the CDK16 kinase domain were performed with a number of the inhibitors
identiﬁed from the initial compound screening. Viable crystals were ﬁrst obtained for a complex containing the
type I inhibitor indirubin E804. The structure of this complex was solved using CDK5 as a phasing model and
reﬁned at a resolution of 2.4 Å with one CDK16 monomer in the asymmetric unit. The electron density maps
for the structure were generally of high quality. The CDK16 chain was modelled between residues Met162–
Glu473, with the exception of regions of poor electron density at the αC helix, Glu199–Ala204, as well as the
activation segment Ser312–Val323. The C-terminus between Ala474–His485, including the afﬁnity tag, could
also not be built. There was clear density for the indirubin E804 inhibitor in the ATP-binding pocket.
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We subsequently obtained crystals of CDK16 with the type II inhibitor rebastinib and were able to solve the
structure of this complex at a resolution of 2.2 Å (see Table 2 for the data collection and reﬁnement statistics
for both structures). The electron density maps were similarly of high quality and showed two CDK16
monomers in the asymmetric unit. CDK16 chain A was modelled between residues Met162–Ala474, with the
exception of regions of poor electron density in the activation segment Ser312–Lys316. CDK16 chain B was
modelled between residues Met162–Ser475, except for residues Lys311–Val322. Both protein chains showed
clear electron density in the ATP-binding pocket for rebastinib. Viable crystals were not obtained with
dabrafenib.
The isolated CDK16 kinase domain shows conformational plasticity
The crystal structures of monomeric CDK16 represent the ﬁrst structures from the PCTAIRE family of CDK
kinases (Figure 6). The kinase domain exhibits the classical bilobal architecture intermixed with short insertions
that help to deﬁne the CDK family fold. The complex with indirubin E804 displays some disorder in the
kinase N-lobe, consistent with its requirement for a cyclin partner. This lobe features a ﬁve-stranded β-sheet
and the αC helix, which is expected to contain the diverged ‘PCTAIRE’ cyclin-binding sequence motif.
However, in the indirubin E804 complex, the αC is reduced to a single helical turn and the preceding
Table 2 Diffraction data collection and refinement statistics (molecular replacement)
Values in parentheses are for highest resolution shell. Abbreviation: R.m.s, root-mean-square.
CDK16–indirubin E804 (PDB ID: 3MTL) CDK16–rebastinib (PDB ID: 5G6V)
Data collection
Beamline Diamond light source, I03 Diamond light source, I02
Wavelength (Å) 0.9800 0.9174
Space group P43212 P21221
Cell dimensions
a, b, c (Å) 47.4, 47.4, 341.3 57.2, 86.9, 146.3
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Number of unique reflections 16 459 (2304) 37 175 (3157)
Resolution (Å)* 20.09–2.40 (2.53–2.40) 28.98–2.20 (2.27–2.20)
Rmerge 0.102 (0.684) 0.093 (0.454)
CC(1/2) 0.996 (0.909) 0.996 (0.818)
I/σI 9.6 (2.1) 9.4 (2.8)
Completeness (%) 99.8 (100) 98.3 (97.4)
Redundancy 6.7 (6.8) 5.2 (4.9)
Refinement
Ligand Indirubin E804 Rebastinib
Resolution (Å) 20.09–2.40 (2.57–2.40) 86.94–2.20 (2.26–2.20)
Number of reflections 16 358 35 328
Rwork/Rfree 19.4/26.3 20.8/27.1
Average B factor (Å2) 72.5 40.433
R.m.s. deviations
Bond lengths (Å) 0.010 0.009
Bond angles (°) 1.21 1.34
Molprobity
Ramachandran favoured (%) 95.5 96.0
Ramachandran allowed (%) 4.5 4.0
*Single crystal.
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PCTAIRE motif instead adopts a loosely extended conformation that is stabilised by crystal packing. In con-
trast, the rebastinib complex has a canonical αC helix that includes the PCTAIRE motif, which probably reﬂects
the additional interactions this region forms with the bound inhibitor. Indeed, the complete N-lobe is well
deﬁned in this structure, including the ﬂexible β3–αC loop insertion that typically supports the interaction of a
CDK with its cyclin. This surface is also stabilised by crystal packing interactions. The predominantly α-helical
C-lobe contains the CDK/MAPK insert, which packs against the αDE and αG helices, as well as a PCTAIRE
family speciﬁc C-terminal extension that stretches behind the αI helix before folding back to terminate beside
the αD helix (Figure 6).
Comparison of the two complexes reveals small differences in the conformations of the N-lobes and marked
differences in the folding of the activation segments (Figure 7A). The rebastinib co-structure displays an
inactive ‘DFG-out, αC-in’ conﬁguration. In this structure, Asp304, Phe305 and Gly306 are ﬂipped into an
inverted conformation relative to an active kinase. The activation segment therefore folds antiparallel to the β1
strand and occludes the front of the ATP pocket. In contrast, in the indirubin E804 complex, this segment
extends below the αC helix to form the expected β6–β9 sheet (Figure 7A). However, a partial inversion of the
DFG motif is still observed in which Asp304 and Phe305 are ﬂipped out, while Gly306 retains its expected con-
formation. Thus, this structure does not conform to a classic type I inhibitor complex. This atypical feature
further suggests that CDK16 is only loosely structured in the absence of cyclin Y and ordered by the bound
inhibitor. For example, in both complexes, the inhibitors help to stabilise the critical salt bridge between the
catalytic lysine (Lys194, β3) and Glu211 (αC). Despite this interaction, the inactive conformations shown by
both kinase structures would not support substrate recruitment.
As well as the variant PCTAIRE motif, the CDK16 fold shows differences to other CDKs in the conformation
of the CDK/MAPK insert (Figure 7B). The CDK/MAPK insert forms an additional protein–protein interaction
surface in the CDK family. The insert in CDK16 contains a well-deﬁned short helix αGH1, whereas the CDK2
insert is predominantly a loop (deﬁned as ‘L14’) best known for its interaction with CKS1 (Figure 7B) [41]. Thus,
the surfaces of CDK2 and CDK16 probably evolved to mediate distinct protein–protein interactions.
Structural basis for inhibitor-binding interactions
The indirubin E804 scaffold is largely planar and binds to the kinase hinge region of CDK16 using three hydro-
gen bonds, including two from the indole-2-one moiety and one from the indole moiety (Figure 8A). These
Figure 6. Structures of the CDK16 kinase domain.
Structure of the CDK16 kinase domain solved in complex with indirubin E804 (A) or rebastinib (B). Selected CDK16 motifs are labelled and
highlighted by different colours.
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groups also present a signiﬁcant hydrophobic surface for van der Waals interactions with the ATP pocket resi-
dues Leu171, Val179, Ala192, Val224, Phe240, Leu293 and Ala303. The hydroxybutyloxime moiety extends
across the expected ribose- and phosphate-binding sites of the ATP pocket. Here, the ﬂipped-out conformation
of Phe305 in the activation segment establishes a cage-like structure around the inhibitor. The binding therefore
features an induced ﬁt that maximises the kinase–inhibitor interaction.
The extended binding mode of the type II inhibitor rebastinib is quite distinct from that of the type I inhibi-
tor, indirubin E804 (Figure 8B). As anticipated, the binding of rebastinib is facilitated by an inverted conform-
ation of the ‘DFG motif’, which creates an extra pocket for inhibitor binding below the αC helix. Rebastinib
forms a total of ﬁve hydrogen bonds with the ATP-binding pocket of CDK16, as similarly observed in the
equivalent ABL structure (Figure 8C) [39]. The carboxamide-substituted pyridine ring forms two hydrogen
bonds with the backbone amide and carbonyl of the ATP-hinge residue, Leu243. The urea moiety’s nitrogens
also form two hydrogen bonds with Glu211 from the αC ‘PCTAIRE’ motif. A further hydrogen bond is
formed between the backbone amide of Asp304 and the urea carbonyl (Figure 8B). The central phenyl ring is
sandwiched between the gatekeeper residue Phe240 and the ﬂipped-out Phe305 (DFG motif ), providing strong
π–π packing interactions. The t-butyl group occupies the hydrophobic pocket vacated by the inverted Phe305.
Finally, the quinoline moiety extends below Glu211 and the αC helix (Figure 8B). CDK16 and ABL show
many side chain differences in this region that could be useful for the future modiﬁcation of rebastinib to more
selectively target CDK16. For example, the binding of the quinoline moiety in ABL is capped by Glu282 at the
N-terminus of the αC (Figure 8C), whereas the smaller Thr207 side chain in CDK16 would allow the quinoline
to be expanded.
Discussion
For many years, the position of CDK16 (PCTAIRE1) within the CDK family was uncertain: the identity of its
cyclin partner remained elusive and its existence was cast in doubt [7]. Now, cyclin Y has been implicated in
binding to both the PCTAIRE1–3 (CDK16–18) and related PFTAIRE1–2 (CDK14–15) family kinases [3,6,42].
Taken together, these kinases belong with CDK5 to an atypical group of CDK proteins related to the yeast
kinase Pho85 [2]. Unusually, these CDKs bind to cyclin partners that are predicted to contain only a single
Figure 7. CDK16 structures show different conformations.
(A) Superposition of the different CDK16 structures (left panel) shows the alternative conformations adopted by the activation
segment when in complex with indirubin E804 (type I inhibitor) or rebastinib (type II inhibitor). Right panel shows the respective
positions of residues in the ‘DFG motif’. (B) Superposition of CDK2 (PDB ID: 5IF1 [59]) and CDK16 structures reveals structural
differences in the CDK/MAPK insert. Colours are indicated by the keys provided.
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cyclin box domain, whereas most cyclins have two domains. The crystal structures of CDK16 reported here
offer the ﬁrst structural view of a kinase from either of the PCTAIRE or PFTAIRE subfamilies (CDK14–18).
Overall, the scaffold of CDK16 bears all of the structural elements expected of a CDK. Furthermore, its cyclin
dependency is strongly supported by the inactive and partly disordered conformation found in the indirubin
E804 complex. The localised unfolding of the PCTAIRE motif in the αC helix is intriguing and quite unlike
the structures of other monomeric CDKs. Other unusual features in the CDK16 structure include a partially
inverted DFG motif and distinct conformations of the large C-terminal extension and the CDK/MAPK insert.
Taken together, these features may suggest an additional stabilising role for the uncharacterised N-terminal
extension of CDK16 or perhaps a missing 14-3-3 protein interaction, which appears necessary for the activa-
tion of both the PCTAIRE and PFTAIRE family kinases [5,8].
The conformational plasticity shown by CDK16 supports its binding to the diverse set of chemical scaffolds
identiﬁed here, including both type I and type II inhibitors. The observed enrichment of known CDK inhibitors
is consistent with both the sequence conservation, and the large amount of chemistry that has been directed
towards this family. None of the identiﬁed scaffolds are reported to be highly selective, suggesting that additional
chemistry would be required to develop a compound for use as a probe of CDK16 function in cells. Most
Figure 8. Interactions of indirubin E804 and rebastinib with the ATP-binding pocket of CDK16.
(A) Indirubin E804 binds to the kinase hinge region of CDK16 forming three hydrogen bonds. An atypical induced ﬁt is
observed in which the activation segment residue Phe305 is ﬂipped out to establish a cage-like structure around the inhibitor.
(B) Rebastinib binds as a type II inhibitor forming a total of ﬁve hydrogen bonds with the ATP-binding pocket of CDK16. The
binding is facilitated by an inverted conformation of the ‘DFG motif’, which creates an extra pocket for inhibitor binding below
the αC helix. (C) Structure of the ABL complex with rebastinib for comparison (PDB ID: 3QRI [39]). The glycine-rich loop shows
a collapsed conformation that forms a cage around the inhibitor. Selected structural motifs are labelled and highlighted by
different colours.
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interestingly, we identiﬁed two clinically tested inhibitors, dabrafenib and rebastinib, as the most potent CDK16
inhibitors both in vitro and in intact cells. Thus, there is potential beneﬁt to test these compounds in the future
in cancers associated with CDK16 overexpression [16]. However, given that dabrafenib and rebastinib are not spe-
ciﬁc inhibitors of CDK16, the identiﬁcation or development of CDK16-selective inhibitors may be necessary.
We also found that the binding of CDK16 to dabrafenib and rebastinib was mutually exclusive with its
binding to the cyclin Y/14-3-3 complex. Such a mechanism has been previously reported for inhibitors of the
CDK2 kinase. For example, Deng et al. [43] have identiﬁed a quinoline-based inhibitor that induces an αC-out
conformation in CDK2 and therefore disrupts the proper interaction of the PSTAIRE motif with cyclin
A. Alexander et al. [44] have additionally identiﬁed many type II inhibitors that bind to a previously unrecog-
nised DFG-out conformation of CDK2 and similarly block its association with cyclin A by removing the poten-
tial for an interaction with the CDK2 activation segment. Dabrafenib and rebastinib are expected to disrupt the
CDK16 interaction with the cyclin Y/14-3-3 complex via similar structural mechanisms. Dabrafenib is expected
to induce an αC-out kinase conformation, as observed in various BRAF complexes [40,45], whereas the
co-structure of CDK16 and rebastinib has conﬁrmed a DFG-out binding mode for this type II inhibitor. Thus,
structural changes in either of the N- or C-terminal lobes of CDK16 appear to affect the binding of cyclin Y/
14-3-3. This is consistent with the homologous structures of CDK5 [46] and Pho85 [47], which have revealed
extensive cyclin interactions across both kinase lobes, as also observed in the CDK2/cyclin A complex [48].
The assembly of the active CDK16/cyclin Y/14-3-3 complex is tightly regulated by phosphorylation sites
within the FL proteins that remain to be structurally characterised. Once activated, the CDK16 kinase performs
critical functions within the brain and testis, including neurite outgrowth [7], retrograde axonal trafﬁcking [10],
exocytosis [11], vesicle transport [12] and spermatogenesis [3]. Furthermore, CDK14, CDK16, CDK18 and
cyclin Y have all been linked to cancer cell proliferation, migration or cancer drug resistance [18,49–54].
Moreover, these effects were reversed by siRNA-mediated knockdown of the respective target [19,20,54–58].
The excellent druggability of CDK16 and chemical scaffolds identiﬁed here provide further opportunity to
better characterise the role of these kinases and suggest the potential to develop more selective CDK16 inhibi-
tors for possible clinical use and as powerful basic research tools.
Database deposition
The atomic co-ordinates and structure factors (codes 3MTL and 5G6V) have been deposited in the Protein
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